M&T Bank Corp Increases Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

M&T Bank Corp lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 111,239 shares of the biopharmaceutical company’s stock after buying an additional 561 shares during the quarter. M&T Bank Corp owned about 0.09% of Halozyme Therapeutics worth $6,367,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. RPg Family Wealth Advisory LLC acquired a new stake in Halozyme Therapeutics during the 3rd quarter worth $1,886,000. Segall Bryant & Hamill LLC grew its holdings in shares of Halozyme Therapeutics by 16.3% during the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock worth $20,330,000 after purchasing an additional 49,856 shares during the last quarter. Creative Planning increased its position in shares of Halozyme Therapeutics by 43.2% during the second quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock worth $1,953,000 after purchasing an additional 11,249 shares in the last quarter. South Street Advisors LLC purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $9,812,000. Finally, Handelsbanken Fonder AB lifted its holdings in shares of Halozyme Therapeutics by 76.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after purchasing an additional 856,200 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analysts Set New Price Targets

HALO has been the topic of several research analyst reports. Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the company from $52.00 to $57.00 in a report on Thursday, September 19th. JMP Securities increased their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. HC Wainwright reissued a “buy” rating and set a $68.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, December 18th. Finally, Piper Sandler upped their target price on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a report on Monday, November 4th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $61.11.

Halozyme Therapeutics Stock Down 0.8 %

Shares of NASDAQ:HALO opened at $46.96 on Monday. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The firm’s 50-day simple moving average is $50.91 and its 200-day simple moving average is $54.18. The company has a market cap of $5.97 billion, a price-to-earnings ratio of 15.55, a PEG ratio of 0.43 and a beta of 1.23.

Insider Activity at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $52.58, for a total value of $525,800.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at $35,583,199.52. This trade represents a 1.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 30,000 shares of company stock worth $1,621,800 over the last 90 days. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.